Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Launched by MAYO CLINIC · Jun 30, 2025

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy)
• • Age 46-60 years old
• • BMI ≥ 30 kg/m2.
• Exclusion Criteria:
• • Past or current use of menopausal hormone therapy
• • Early or premature menopause
• • History of chemically induced menopause
• • Impaired renal function (GFR ≤29)
• • Thyroid-stimulating hormone ≥7 with low free T4
• • Diabetes
• • Cardiovascular disease
• • Elevated blood pressure (\>170/\>95)
• • Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease
• • \>5% change in weight during the 3 months prior to screening
• • Other anti-obesity medication use within the past 3 months
• • History of bariatric surgery
• • History of malignant neoplasms within the past 5 years prior to screening
• • Current use of supplements known to affect weight
• • Personal or family history of medullary thyroid cancer.
• • Wheelchair bound
• • Vision loss